Montefiore Einstein Neuroscience Center Team
At the Montefiore Einstein Neuroscience Center, we are committed to applying the latest biomedical breakthroughs and technological innovations to advance our understanding of the underlying mechanisms mediating the full spectrum of neuropsychiatric disorders. Our development of revolutionary diagnostic and treatment paradigms to prevent, delay, ameliorate and eventually cure diseases that are frequently chronic and debilitating provides hope and inspiration to patients, families, and interconnected and particularly innovative national and international biomedical research communities.
We have a long history of developing state-of-the-art and cross-disciplinary research and clinical innovations led by the leadership of the associated departments, disease centers and institutes. Moreover, each successive chair from our founding to the present time represents internationally renowned physician-scientists who have pioneered novel and paradigm-shifting programs that are uncovering the secrets of normal brain function throughout the lifespan and the biological basis of numerous complex and challenging disease entities that are beginning to revolutionize intersectional therapeutic initiatives.
Our center continues to elevate the standard for biomedical creativity and discovery established by our visionary founders, who defined major new fields of interdisciplinary scholarship that have progressively expanded the scope of what encompasses modern neuroscience disciplines today, giving rise to explosive new understandings of disease mechanisms that led to disease-modifying therapies and eventual cures.
Novel examples of these intersectional approaches include enhancing brain health and resilience mechanisms active during critical periods throughout the lifespan, epigenomic, neuroregenerative and cellular/neural network rejuvenation paradigms, advanced real-time and environmentally responsive cognitive biotechnologies, additional synthetic biology/emerging AI, advanced robotics and nano-therapeutic platforms. In addition, we are pioneering next-generation and more biologically relevant biomarker and therapeutic target discoveries to complement our evolving therapeutic applications.